MedTrace Logo

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

NCT05900921 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2023-06-13

No results posted yet for this study

Summary

The purpose of this study is to explore the myeloprotective effects of trilaciclib in advanced squamous non-small cell lung cancer patients receiving a combination therapy of chemotherapy(carboplatin+paclitaxel) and immune checkpoint inhibitor (tislelizumab), as well as enhancing antitumor efficacy and possible immunological synergies.

Conditions

  • Advanced Squamous Non-Small-Cell Lung Cancer

Interventions

DRUG

Trilaciclib

IV infusion, d1

DRUG

Carboplatin

IV infusion, d1

DRUG

Paclitaxel

IV infusion, d1

DRUG

Tislelizumab

IV infusion, d1

Sponsors & Collaborators

  • Chengdu First People's Hospital

    collaborator OTHER

  • Chengdu Second people's hospital

    collaborator UNKNOWN

  • Chengdu Seventh People's Hospital

    collaborator UNKNOWN

  • Mianyang Central Hospital

    collaborator OTHER

  • Shaanxi Provincial Cancer Hospital

    collaborator OTHER

  • Shandong Cancer Hospital and Institute

    collaborator OTHER

  • Heilongjiang Provincial Cancer Hospital

    collaborator UNKNOWN

  • Enshi Central Hospital

    collaborator UNKNOWN

  • Neijiang Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN

  • Sichuan University

    lead OTHER

Principal Investigators

  • Yongsheng Wang · West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-10-31
Completion
2025-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05900921 on ClinicalTrials.gov